We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Mitomycin C intravesical therapy in noninvasive bladder cancer after failure on thiotepa.
- Authors
Issell, Brian F.; Prout, George R.; Soloway, Mark S.; Cummings, Kenneth B.; Brannen, George; Veenema, Ralph; Flanagan, Malachi; Block, Norman L.; Summers, Jack L.; Levin, Elizabeth A.; Dianne Defuria, M.; Issell, B F; Prout, G R Jr; Soloway, M S; Cummings, K B; Brannen, G; Veenema, R; Flanagan, M; Block, N L; Summers, J L
- Abstract
Mitomycin C 40 mg in 40 ml water was administered intravesically every week for 8 consecutive weeks to 60 patients with superficial bladder cancer. All patients had failed treatment with intravesical thiotepa and had evaluable disease. An objective response of 50% or greater reduction in measured tumor mucosal involvement was obtained in 68% of patients. Forty-two percent of the patients achieved a complete response, and this included 50% of patients with Grade III disease and 70% of patients with a T1 tumor. Median response duration in complete responders was 12.2 months with a range of 3.5 to 24.3 + months. Fifty-five percent of patients are still responding. Therapy was generally well tolerated, and in contrast to thiotepa, myelosuppression was not the dose-limiting effect. One third of all patients experienced symptoms of local irritation, and skin reactions were seen in 12% of patients.
- Publication
Cancer (0008543X), 1984, Vol 53, Issue 5, p1025
- ISSN
0008-543X
- Publication type
journal article
- DOI
10.1002/1097-0142(19840301)53:5<1025::AID-CNCR2820530502>3.0.CO;2-D